Journal article
Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function
JM Hodge, Y Wang, M Berk, FM Collier, TJ Fernandes, MJ Constable, JA Pasco, S Dodd, GC Nicholson, RL Kennedy, LJ Williams
Biological Psychiatry | Published : 2013
Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs) are widely used antidepressants and one of the most commonly used medications. There is growing concern that SSRIs, which sequester in bone marrow at higher concentrations than brain or blood, increase bone fragility and fracture risk. However, their mechanism of action on human osteoclasts (OC) and osteoblasts (OB) differentiation remains unclear. Methods: Expression of serotonin receptors (5-HTR), transporter (5-HTT), and tryptophan hydroxylase 1 (TPH1) was assessed in human OC (precursors and mature) and OB (nonmineralizing and mineralizing) by polymerase chain reaction. OC formation and resorption was measured in the presence of..
View full abstractGrants
Funding Acknowledgements
[ "This work was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC).", "MB has received Grant/Research Support from the National Institutes of Health, Simons Foundation, Cooperative Research Centres for Mental Health, Stanley Medical Research Institute, Medical Benefits Fund, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, Servier, and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, and Pfizer and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay, and Wyeth." ]